Literature DB >> 12067295

Requirement for TNF-Tnfrsf1 signalling for sclerosing cholangitis in mice chronically infected by Cryptosporidium parvum.

E M Ponnuraj1, A R Hayward.   

Abstract

An increase in mRNA levels for TNF and Tnfrsf1 in the bile ducts of Tnfsf5-/-(CD40 ligand or CD154 knockout) mice developing cholangitis following infection by Cryptosporidium parvum (CP) is accompanied by staining for TNFalpha in areas of inflammation. To determine whether TNF contributed to the bile duct damage seen in chronically-infected animals, we bred B6 mice with disrupted genes for Tnfrsf1a, Tnfrsf1b and Tnfsf5. Following CP infection, the Tnfsf5-/- Tnfrsf1a & 1b-/- mice were spared from cholangitis, even though their intestinal and bile duct infection by CP persisted. Mice with disruptions of Tnfsf5, and either Tnfrsf1a or Tnfrsf1b, developed bile duct sclerosis similar to that seen in CD40 and Tnfsf5 knockouts. Our data indicate that signalling through either TNF receptor is sufficient for the bile duct damage that follows chronic CP infection in mice, with disruption of the Tnfsf5 molecule.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067295      PMCID: PMC1906254          DOI: 10.1046/j.1365-2249.2002.01861.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

Review 1.  The immunobiology of bile and biliary epithelium.

Authors:  S Reynoso-Paz; R L Coppel; I R Mackay; N M Bass; A A Ansari; M E Gershwin
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

2.  Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages.

Authors:  A Mukhopadhyay; J Suttles; R D Stout; B B Aggarwal
Journal:  J Biol Chem       Date:  2001-07-03       Impact factor: 5.157

Review 3.  Tumor necrosis factors: developments during the last decade.

Authors:  B B Aggarwal; K Natarajan
Journal:  Eur Cytokine Netw       Date:  1996 Apr-Jun       Impact factor: 2.737

4.  NF-kappaB is activated in cholestasis and functions to reduce liver injury.

Authors:  H Miyoshi; C Rust; M E Guicciardi; G J Gores
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

5.  A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies.

Authors:  T Orth; M Neurath; P Schirmacher; P R Galle; W J Mayet
Journal:  J Hepatol       Date:  2000-12       Impact factor: 25.083

6.  Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM.

Authors:  A R Hayward; J Levy; F Facchetti; L Notarangelo; H D Ochs; A Etzioni; J Y Bonnefoy; M Cosyns; A Weinberg
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

7.  Intact intestinal mRNAs and intestinal epithelial cell esterase, but not Cryptosporidium parvum, reach mesenteric lymph nodes of infected mice.

Authors:  E M Ponnuraj; A R Hayward
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

Review 8.  Anti-tumor necrosis factor therapies.

Authors:  P C Taylor
Journal:  Curr Opin Rheumatol       Date:  2001-05       Impact factor: 5.006

9.  Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis.

Authors:  H O Nilsson; J Taneera; M Castedal; E Glatz; R Olsson; T Wadström
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

10.  Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro.

Authors:  K Matsumoto; H Fujii; G Michalopoulos; J J Fung; A J Demetris
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

View more
  5 in total

Review 1.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

2.  The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice.

Authors:  Peter Fickert; Andrea Thueringer; Tarek Moustafa; Dagmar Silbert; Judith Gumhold; Oleksiy Tsybrovskyy; Margitta Lebofsky; Hartmut Jaeschke; Helmut Denk; Michael Trauner
Journal:  Lab Invest       Date:  2010-04-05       Impact factor: 5.662

3.  miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytes.

Authors:  Guoku Hu; Ai-Yu Gong; Jun Liu; Rui Zhou; Caishu Deng; Xian-Ming Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-01-28       Impact factor: 4.052

Review 4.  Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Peter Fickert
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

5.  Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature.

Authors:  Caroline Klindt; Björn-Erik Jensen; Timo Brandenburger; Torsten Feldt; Alexander Killer; Lars Schimmöller; Gerald Antoch; Tina Senff; Sandra Hauka; Jörg Timm; Bahne Hendrik Bahners; Maximilian Seidl; Irene Esposito; Tom Luedde; Johannes G Bode; Verena Keitel
Journal:  Clin Case Rep       Date:  2021-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.